Drugs Made In America Acquisition II Corp. (DMII): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of DMII were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who owns DMII
69 funds and institutions reported DMII shares worth $459M at the end of Q2 2026, about 72% of the company. The largest holder is Karpus Management, Inc. with 4.4%.
Funds and institutions (13F) 72%Everyone else 28%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Karpus Management, Inc. | 2.79M | 4.38% | $28M | +7% |
| MMCAP International Inc. SPC | 2.70M | 4.24% | $27.2M | No change |
| Magnetar Financial LLC | 2.70M | 4.24% | $27.2M | No change |
| Glazer Capital, LLC | 2.34M | 3.68% | $23.6M | -0% |
| Highbridge Capital Management LLC | 2.24M | 3.52% | $22.6M | +896% |
| Millennium Management LLC | 1.99M | 3.13% | $20.1M | +1% |
| Hudson Bay Capital Management LP | 1.97M | 3.09% | $19.8M | No change |
| Wolverine Asset Management LLC | 1.86M | 2.91% | $18.7M | +3% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 1.50M | 2.35% | $15.1M | No change |
| Polar Asset Management Partners Inc. | 1.50M | 2.35% | $15.1M | No change |
| D. E. Shaw & Co., Inc. | 1.48M | 2.32% | $14.8M | +6% |
| AQR Arbitrage LLC | 1.13M | 1.78% | $11.4M | +2% |
| Aristeia Capital, L.l.c. | 1.10M | 1.73% | $11.1M | No change |
| Crossingbridge Advisors, LLC | 1.10M | 1.73% | $11.1M | +214% |
| First Trust Capital Management L.P. | 1.07M | 1.68% | $10.7M | No change |
| Davidson Kempner Capital Management LP | 1.00M | 1.57% | $10.1M | No change |
| OMERS ADMINISTRATION Corp | 1.00M | 1.57% | $10.1M | No change |
| Picton Mahoney Asset Management | 888,000 | 1.39% | $8.9M | +1% |
| Two Sigma Investments, LP | 886,544 | 1.39% | $8.9M | No change |
| Moore Capital Management, LP | 750,000 | 1.18% | $7.5M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No DMII insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DMII short interest
Low short interest. 0.2% of DMII shares are sold short: about 1 share in 657. Over the last 12 reports the number of shares short went up 65%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 96,992 DMII shares were sold short, 0.2% of the shares outstanding, down 12.8% from the report before. At the average daily volume of 224,401 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 96,992 | 0.15% | -13% | 224,401 | 1.0 |
| Oct 15, 2026 | 111,243 | 0.17% | -8% | 232,006 | 1.0 |
| Sep 30, 2026 | 121,549 | 0.19% | -4% | 57,563 | 2.1 |
| Sep 15, 2026 | 126,137 | 0.20% | +6% | 38,736 | 3.3 |
| Aug 31, 2026 | 119,323 | 0.19% | -2% | 64,286 | 1.9 |
| Aug 14, 2026 | 121,957 | 0.19% | -10% | 764 | 159.6 |
| Jul 31, 2026 | 135,284 | 0.21% | +191% | 95,778 | 1.4 |
| Jul 15, 2026 | 46,508 | 0.07% | -21% | 29,574 | 1.6 |
| Jun 30, 2026 | 58,818 | 0.09% | -3% | 208,907 | 1.0 |
| Jun 15, 2026 | 60,836 | 0.10% | -6% | 8,355 | 7.3 |
| May 29, 2026 | 65,009 | 0.10% | +11% | 20,485 | 3.2 |
| May 15, 2026 | 58,729 | 0.09% | +46% | 204,282 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Drugs Made In America Acquisition II company events
Drugs Made In America Acquisition II filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Apr 28, 2026.
- Apr 28, 2026AgreementAs previously disclosed, on November 17, 2025, Drugs Made in America Acquisition II Corp. appointed Saleem Elmasri as Chief Financial Officer of the Company and entered into a Master Services Agreement with Titan Advisory Services LLC for the provision of such principal financial and accounting… Filing
- Apr 3, 2026AgreementAs previously disclosed, on March 11, 2026, Drugs Made In America Acquisition II Corp. issued an unsecured convertible note to Alpha Multi Family Office in the principal amount of $150,000. Filing
- Mar 17, 2026AgreementDrugs Made In America Acquisition II Corp. issued an unsecured convertible note to Alpha Multi Family Office in the principal amount of $150,000. Filing
- Mar 6, 2026AnnouncementAs previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026, Drugs Made In America Acquisition II Corp. announced that, between the completion of its initial public offering on September 26, 2025 and December 31, 2025, the sponsor to… Filing
- Mar 6, 2026LeadershipDepartures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Nov 18, 2025LeadershipGlenn Worman, the Chief Financial Officer and principal financial and accounting officer of Drugs Made In America Acquisition II Corp. delivered to the Company a notice of resignation from his position as Chief Financial Officer and principal financial and accounting officer of the Company. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Drugs Made In America Acquisition II financials
Famous investors that hold DMII
1 of the 50 well-known investors we track reported holding DMII in their latest 13F filing. The largest position is Israel Englander's, worth $20.5M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 4.00M | $20.5M | 0.0% | +0% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DMII in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | KARPUS MANAGEMENT, INC. | 13G | 5.2% |
| Nov 13, 2026 | KARPUS MANAGEMENT, INC. | 13G | 5.2% |
Questions about Drugs Made In America Acquisition II Corp. (DMII) stock
Who owns the most DMII stock?
The largest reported owner of Drugs Made In America Acquisition II Corp. (DMII) is Karpus Management, Inc., with 4.4% of the company. In total, 69 funds and institutions reported holding DMII at the end of Q2 2026, together about 72% of the shares. See the largest owners.
Are DMII insiders buying or selling?
No DMII insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in DMII?
As of Oct 30, 2026, 96,992 DMII shares were sold short, 0.2% of the shares outstanding, down 12.8% from the report before. At the average daily volume of 224,401 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold DMII?
1 of the 50 well-known investors we track reported DMII in their latest 13F filing, including Israel Englander. The largest position is worth $20.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.